2024
Proceedings from an international consensus meeting on ablation in urogenital diseases
Iezzi R, Contegiacomo A, De Filippis A, Gunn A, Atwell T, Mcclure T, Jing Z, Posa A, Scrofani A, Maresca A, Madoff D, Goldberg S, Kelekis A, Filippiadis D, Sala E, Ahmed M. Proceedings from an international consensus meeting on ablation in urogenital diseases. Insights Into Imaging 2024, 15: 267. PMID: 39514046, PMCID: PMC11549275, DOI: 10.1186/s13244-024-01841-2.Peer-Reviewed Original ResearchInternational Consensus MeetingAblation techniqueIntermediate-risk prostate cancerImage-guided ablation techniquesPreoperative surgical riskManagement of oncological diseasesRenal cell carcinomaConsensus meetingTraditional surgical treatmentGenitourinary tract diseaseFibroid SymptomCell carcinomaProstate cancerSurgical riskAblation therapyImprove patient outcomesTumor managementSurgical treatmentMechanism of actionEffective alternativeTherapeutic alternativeSite of applicationEffective treatmentUrogenital diseasesOncological diseasesShort-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison.
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Ibrahim S, Fortune B, Talenfeld A, Madoff D, Johnson M, Sedrakyan A. Short-Term Out-of-Pocket and Total Costs of Care After Ablation, Resection, or Transplant for Early-Stage Hepatocellular Carcinoma: A National SEER-Medicare Cost Comparison. American Journal Of Roentgenology 2024, 223: e2431272. PMID: 38899842, DOI: 10.2214/ajr.24.31272.Peer-Reviewed Original ResearchEarly-stage hepatocellular carcinomaHepatocellular carcinomaPost-procedure periodIndex procedureOut-of-pocket costsPatient out-of-pocket costsDrivers of high costsDays post-procedureSubgroup of patientsTreated with ablationPropensity-matched subgroupsU.S. population-based studyPopulation-based studySurgical resectionMultivariate linear regression modelSurgical treatmentPrognostic indicatorPost-procedureTreatment modalitiesTreatment optionsSEER-MedicareResectionMultivariate analysisTransplantationPropensity-score
2019
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west
Lu J, Zhang XP, Zhong BY, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng SQ, Teng GJ. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019, 4: 721-730. PMID: 31387735, DOI: 10.1016/s2468-1253(19)30178-5.Peer-Reviewed Original ResearchMeSH KeywordsAnilidesAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticEndovascular ProceduresHepatectomyHepatic ArteryHumansInfusions, Intra-ArterialLiver NeoplasmsLiver TransplantationNivolumabPatient Care TeamPhenylurea CompoundsPortal VeinPyridinesQuinolinesRadiotherapy, AdjuvantSorafenibStentsVenous ThrombosisConceptsPortal vein tumor thrombosisTumor thrombosisHepatocellular carcinomaOptimise treatment strategiesTranscatheter arterial therapyAdvanced hepatocellular carcinomaManagement of patientsArterial therapySurgical treatmentTreatment strategiesPhysician preferenceNovel treatmentsCarcinomaThrombosisMultidisciplinary teamPatientsReimbursement schemesTreatmentRevascularisationComorbiditiesManagementPrognosisRadiotherapyActive managementTherapy